68.2% of GRIFOLS revenues come from the US and Canada. Covid19 cases there seem to be decreasing. The company is delaying more and more its deadline of results for the phase III of the inmunoglobulina antiCovid-19, now until spring 2021.
If GRLS results are positive or better than expected (specially Q4 ones), I expect a jump from 21.61 to 26 in a matter of 2 weeks. The 2020 annual earnings are due on February 26. Grifols has a key support on 21.61 and then a structural support on 20.77. This week we'll see how it goes but as soon as it touches 21.61 is already a buy in my opinion and hold until Feb 26. Then depending on the results, sell or hold until its price objective recommendations which are around 30€.
Note: RSI-14 is also below 30, so we might expect a change of trend sooner than later.
Good luck traders and long-term investors!
If GRLS results are positive or better than expected (specially Q4 ones), I expect a jump from 21.61 to 26 in a matter of 2 weeks. The 2020 annual earnings are due on February 26. Grifols has a key support on 21.61 and then a structural support on 20.77. This week we'll see how it goes but as soon as it touches 21.61 is already a buy in my opinion and hold until Feb 26. Then depending on the results, sell or hold until its price objective recommendations which are around 30€.
Note: RSI-14 is also below 30, so we might expect a change of trend sooner than later.
Good luck traders and long-term investors!
